Scarica l'app Stockscreener
81.12
1.99%
-1.65
Dopo l'orario di chiusura:
81.12
Precedente Chiudi:
$82.77
Aprire:
$80.892
Volume 24 ore:
403.27K
Relative Volume:
0.42
Capitalizzazione di mercato:
$3.56B
Reddito:
$535.08M
Utile/perdita netta:
$-48.27M
Rapporto P/E:
-71.57
EPS:
-1.1335
Flusso di cassa netto:
$-31.54M
1 W Prestazione:
-2.51%
1M Prestazione:
+19.72%
6M Prestazione:
+11.09%
1 anno Prestazione:
+49.31%
Intervallo 1D:
$80.81
$83.34
Intervallo di 1 settimana:
$80.81
$91.53
Portata 52W:
$48.20
$91.53
Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile
Nome
Tarsus Pharmaceuticals Inc
Settore
Industria
Telefono
(949) 409-9820
Indirizzo
15440 LAGUNA CANYON ROAD, IRVINE
Compare TARS vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TARS
Tarsus Pharmaceuticals Inc
|
81.12 | 3.63B | 535.08M | -48.27M | -31.54M | -1.1335 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-24 | Ripresa | Oppenheimer | Outperform |
| 2025-12-09 | Iniziato | Barclays | Overweight |
| 2025-11-20 | Iniziato | Mizuho | Outperform |
| 2025-06-02 | Ripresa | Oppenheimer | Outperform |
| 2025-05-27 | Ripresa | H.C. Wainwright | Buy |
| 2023-11-20 | Iniziato | Goldman | Neutral |
| 2023-07-18 | Iniziato | William Blair | Outperform |
| 2023-05-18 | Iniziato | Guggenheim | Buy |
| 2022-08-01 | Iniziato | Barclays | Overweight |
| 2021-12-21 | Iniziato | H.C. Wainwright | Buy |
| 2021-11-23 | Iniziato | Oppenheimer | Outperform |
| 2020-11-10 | Iniziato | BofA Securities | Buy |
| 2020-11-10 | Iniziato | Jefferies | Buy |
| 2020-11-10 | Iniziato | Ladenburg Thalmann | Buy |
| 2020-11-10 | Iniziato | Raymond James | Strong Buy |
Mostra tutto
Tarsus Pharmaceuticals Inc Borsa (TARS) Ultime notizie
Tarsus Pharmaceuticals Finalizes Acquisition of Alkeus Pharmaceuticals with $270M Cash and Stock Deal - Kalkine Media
Tarsus Pharmaceuticals COO Neervannan Seshadri Offloads 4,564 Shares at $85 Each (NASDAQ: TARS) - Kalkine Media
Tarsus Pharmaceuticals CEO Bobak Azamian Executes Open-Market Sale of 10,000 Shares at $90.27-$91.27 (NASDAQ: TARS) - Kalkine Media
Tarsus Pharmaceuticals CMO Executes Stock Sales Under Dual 10b5-1 Trading Plans - Kalkine Media
Tarsus (NASDAQ: TARS) CEO sells 10,000 shares under 10b5-1 plan - Stock Titan
Jefferies raises Tarsus Pharmaceuticals price target on guidance By Investing.com - Investing.com Nigeria
Tarsus Pharmaceuticals gains analyst boost afte... - Pluang
TARS Maintains by Jefferies -- Price Target Raised to $105 - GuruFocus
Tarsus Finalizes Alkeus Acquisition, Expanding Eyecare Pipeline - VisionMonday.com
TARS Stock Drops After Culper Research Accuses Tarsus Of Illegal Medicare Copay Scheme - Stocktwits
Tarsus Pharmaceuticals stock hits all-time high at 85.29 USD By Investing.com - Investing.com South Africa
Tarsus Pharmaceuticals CEO Bobak R. Azamian Offloads 10,000 Shares at $80.06 Each (NASDAQ: TARS) - Kalkine Media
Officer at Tarsus (NASDAQ: TARS) lines up six-figure stock sale - Stock Titan
After recent sales, Tarsus (NASDAQ: TARS) officer's spouse plans another stock trade - Stock Titan
About $943K in stock set for sale at Tarsus (TARS) - Stock Titan
Planned Tarsus (TARS) officer sale covers 4,564 shares - Stock Titan
Tarsus Pharmaceuticals Shares Rise After Closing Alkeus Pharmaceuticals Acquisition - marketscreener.com
Tarsus Pharmaceuticals stock hits all-time high at 85.29 USD - Investing.com
Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care - The Manila Times
A potentially blinding eye disease has no FDA-approved therapy. Tarsus bought a company developing one. - Stock Titan
Tarsus Pharmaceuticals (TARS) CEO sells 10,000 shares in plan trade - Stock Titan
Shareholder plans new stock sale at Tarsus (NASDAQ: TARS) - stocktitan.net
Former Tarsus (NASDAQ: TARS) officer plans another stock sale - Stock Titan
Tarsus (NASDAQ: TARS) exec plans $431K sale after recent $340K stock cash-out - Stock Titan
Tarsus (NASDAQ: TARS) officer lines up another stock sale - Stock Titan
Tarsus to Participate in Upcoming Investor Conferences - The Manila Times
Ex-officer lines up third multimillion sale in Tarsus (NASDAQ: TARS) stock - Stock Titan
Planned $340K insider stock sale at Tarsus (NASDAQ: TARS) from vested pay - stocktitan.net
Form 144 | Tarsus Pharmaceuticals(TARS.US) Insider Proposes to Sell 5.75 Million in Common Stocks - Moomoo
After $3.8M sale, Tarsus (TARS) ex-officer plans more selling - Stock Titan
Tarsus (TARS) Technicals: Finishes 1.69% Up at $72.70 in the Latest Session; Next Test: Support at $69.06 and Resistance at $76.34 Frame the Range in Latest TradingVWAP Bounce - vinanet.vn
Tarsus (NASDAQ: TARS) ex-officer plans sale of 53K shares - Stock Titan
Form 144 | Tarsus Pharmaceuticals(TARS.US) Insider Proposes to Sell 3.82 Million in Common Stocks - Moomoo
Midday Stock Roundup: Eledon Falls 3.5% - Orange County Business Journal
TimesSquare Capital Management LLC Takes $23.25 Million Position in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
Why Tarsus Pharmaceuticals (TARS) Is Up 6.8% After Raising XDEMVY 2026 Sales GuidanceAnd What's Next - Sahm
Tarsus Pharmaceuticals (TARS) Shares Just Moved, What Is Behind The Attention? - Sahm
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Q2 2026 Tarsus Pharmaceuticals, Inc. Earnings Call Transcript - GuruFocus
Tarsus Pharmaceuticals (TARS) Stock Looks Reasonable On Sales While Earnings Stay Weak - Yahoo Finance
William Blair Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating - Moomoo
Janus Henderson Group Ltd. (TARS) discloses 6.5% beneficial stake in Tarsus - Stock Titan
Wasatch Advisors LP Buys New Holdings in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
How (TARS) Movements Inform Risk Allocation Models - Stock Traders Daily
Mizuho Securities Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $100 - Moomoo
Tarsus Pharmaceuticals (TARS) Holds Above $65 Support After Modest Pullback to $68.68Gap Up Stocks - vinanet.vn
TARS Maintained by Oppenheimer -- Price Target Raised to $100 - GuruFocus
Oppenheimer Adjusts PT on Tarsus Pharmaceuticals to $100 From $97, Keeps Outperform Rating - marketscreener.com
Oppenheimer Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Raises Target Price to $100 - Moomoo
Tarsus Pharmaceuticals (TARS) Surges 4.6% to $67.76, Pressing Against ResistanceChandelier Stop - vinanet.vn
Tarsus Pharmaceuticals Signs Agreement to Acquire Alkeus Pharmaceuticals - Global Legal Chronicle
Tarsus Pharmaceuticals Inc Azioni (TARS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):